Please login to the form below

Not currently logged in
Email:
Password:

prostate cancer

This page shows the latest prostate cancer news and features for those working in and with pharma, biotech and healthcare.

CHMP backs Sanofi’s all-oral sleeping sickness drug

CHMP backs Sanofi’s all-oral sleeping sickness drug

Johnson &Johnson got a positive opinion on its non-metastatic castration-resistant prostate cancer (CRPC) drug Erleada (apalutamide), setting up EU approval to follow its FDA green light earlier in the ... Among these, Novartis’CDK4/6 inhibitor Kisqali

Latest news

  • AZ drug matched to cancer mutation passes phase 2 test AZ drug matched to cancer mutation passes phase 2 test

    AZ drug matched to cancer mutation passes phase 2 test. More data from promising class of targeted small molecule drugs. ... AKT E17K is present in about 1% of all tumours and is particularly common in prostate cancer.

  • Soon-Shiong presents first data on cancer memory vaccine at SITC Soon-Shiong presents first data on cancer memory vaccine at SITC

    Soon-Shiong presents first data on cancer memory vaccine at SITC. Novel cocktail shows modest gains in prostate cancer. ... Patrick Soon-Shiong. In the prostate cancer trial, which enrolled patients with at least three prior therapies, eight of 10

  • Novartis: pipeline will generate 60 filings in three years Novartis: pipeline will generate 60 filings in three years

    interleukin-1 beta antibody for non-small cell lung cancer. ... 177. Lu-PSMA-617, a potential first-in-class drug for the treatment of metastatic castration-resistant prostate cancer (CRPC).

  • Bayer preps filings for new prostate cancer drug Bayer preps filings for new prostate cancer drug

    Bayer preps filings for new prostate cancer drug. If approved, will challenge Xtandi and Erleada. ... Armed with new phase 3 data, Bayer has said it intends to press ahead with regulatory filings for its anti-androgen drug darolutamide in early-stage

  • AZ and Clovis PARP inhibitors show their mettle at ESMO AZ and Clovis PARP inhibitors show their mettle at ESMO

    Prostate cancer win. Clovis had its own clinical win to talk about at ESMO, revealing data from the TRITON2 trial of Rubraca as a monotherapy in men with BRCA1/2 mutated ... metastatic castration-resistant prostate cancer, who have received at least one

More from news
Approximately 50 fully matching, plus 320 partially matching documents found.

Latest Intelligence

  • Erectile dysfunction, constipation, vaginal dryness and other laughing matters Erectile dysfunction, constipation, vaginal dryness and other laughing matters

    Billy Connolly received the news of his diagnosis for dementia and prostate cancer on the same day:. ... And on the Wednesday I got news that I had prostate cancer and Parkinson’s disease… But when we went into the living room I went, phrrhrht, ”he

  • Deal Watch February 2017 Deal Watch February 2017

    In February, it granted North American rights to Zoladex, a goserelin acetate implant for prostate and breast cancer and benign gynaecological disorders, to US company TerSera Therapeutics. ... Licence. 358. AstraZeneca/ TerSera Therapeutics. Zoladex,

  • Deal Watch September 2016 Deal Watch September 2016

    At a lower disclosed headline value of $310m BioNTech licensed its mRNA-based cancer vaccines platform to Genentech. ... Janssen granted Tracon Pharmaceuticals the rights to develop two oncology programmes for prostate cancer and haematological

  • Deal Watch August 2016 Deal Watch August 2016

    35! Although Pfizer pointed to the $2.2bn of Xtandi sales for advanced metastatic prostate cancer, this product has been under licence to Astellas since 2009, including a US profit share ... Headline £m. Medivation (US). Pfizer (US). Company acquisition.

  • Deal Watch May 2016 Deal Watch May 2016

    The prize of course is the one marketed product in Medivation's portfolio, Xtandi [enzalutamide for the treatment of advanced prostate cancer] with sales estimated to reach $1.5bn and already ... 110. CSPC Pharmaceutical/ Watson [Allergan]. Licence.

More from intelligence
Approximately 1 fully matching, plus 37 partially matching documents found.

Latest appointments

  • Dendreon appoints new R&D lead Dendreon appoints new R&D lead

    urologists who are uniquely positioned to deliver long-term care to men with prostate cancer. ... stage prostate cancer, with the hope of curing more men of the disease.”.

  • Astellas bolsters oncology clinical development leadership Astellas bolsters oncology clinical development leadership

    breast cancer, leukaemia, lung cancer and prostate cancer. ... of Medicine and the University of Texas MD Anderson Cancer Center.

  • Astellas promotes John Demaree Astellas promotes John Demaree

    Demaree was promoted from his position as executive director of oncology marketing, where he oversaw the launch of prostate cancer drug Xtandi (enzalutamide) and promotion of lung cancer therapy Tarceva (erlotinib). ... Mark Reisenauer, senior vice

  • MDxHealth creates new global commercial team MDxHealth creates new global commercial team

    MDxHealth has created a new global commercial team to drive the launch of SelectMDx, its new prostate cancer test. ... the commercialisation of a molecular diagnostic test for prostate cancer across Europe.”.

  • Dr Hamina Patel moves from J&J to Evgen Pharma Dr Hamina Patel moves from J&J to Evgen Pharma

    She joins the firm from Johnson and Johnson, where she was director of drug development, oncology, where she helped to build a broad portfolio of indications for its cancer drug Velcade. ... interest in prostate cancer.

More from appointments
Approximately 0 fully matching, plus 11 partially matching documents found.

Latest from PMHub

More from PMHub
Approximately 7 fully matching, plus 7 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Future Market Insights

Future Market Insights is the premier provider of market intelligence and consulting services, serving clients in over 150 countries. FMI...

Latest intelligence

OUTiCO win Best in UK Pharmaceutical Outsourcing award
The Corporate LiveWire Healthcare and Life Sciences Awards celebrate global companies and individuals who have excelled over the past 12 months....
artificial-intelligence-in-healthcare.jpg
Artificial Intelligence in Healthcare
Artificial intelligence is already out-diagnosing experts, but would you put a computer in charge of your healthcare? The good, the bad; we take a look....
World Pancreatic Cancer Day 2018: Combating misconceptions in pancreatic cancer
Patients diagnosed with pancreatic cancer face a dismal prognosis, with the disease having the lowest survival rate of all major cancers. In spite of this, pancreatic cancer research is chronically...

Infographics